Given that APOE ε4 status and plasma Aβ1–42 level enhanced the success rate in early stage AD, we further examined the contribution of combining APOE ε4 allele count and plasma Aβ1–42 to the detection of PET+ cases in those clinically suspected MCI and mild AD. The gene discussed is APOE; the disease is Alzheimer disease.